Shorts will run scared today.
However, similar to the approach in rGBM, VB-111 may require an additional targeted therapy to exert its optimal efficacy in this disease setting, such as Avastin, recently approved based on the AURELIA study.
Keeps $13 target, but read through the lines. PIG.
Many longs don't understand how wack it's balance sheet really is. You add to that the warrants that are converted this month & will be ready for sale if not sold already, PLUS $40 mil ATM PLUS $100 million shelf. This is the time to SELL this company.
DGLY IR says BIG news.
I wonder if everyone buying $CLDN at this price realizes it could technically be worth $0 next month if the trial is a complete failure?
The Times: CTI BioPharma (CTIC) may announce positive news on a drug or a obligatory bid.
BIOC market cap is over $100 million after the dilution. This is why it only moved .40 on 12 million shares. The warrant holders? Are converting from $1.56 & selling to you. This is a $1.50 stock.
Let's see...they said 401 data mid year & more at ASH. 501 data in Nov. 801 IND this year & that is why they raised the extra cash. My thoughts....cash rich biotech with no debt. Several catalysts into mid & end of year. I like this stock here and I own it around $14.